202 related articles for article (PubMed ID: 32394535)
1. The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications.
Dean G; Hanauer S; Levitsky J
Hepatology; 2020 Sep; 72(3):1127-1138. PubMed ID: 32394535
[TBL] [Abstract][Full Text] [Related]
2. The Microbiome and Primary Sclerosing Cholangitis.
Ali AH; Carey EJ; Lindor KD
Semin Liver Dis; 2016 Sep; 36(4):340-348. PubMed ID: 27997974
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Shah A; Macdonald GA; Morrison M; Holtmann G
Am J Gastroenterol; 2020 Jun; 115(6):814-822. PubMed ID: 32250997
[TBL] [Abstract][Full Text] [Related]
5. The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts.
Hov JR; Karlsen TH
Semin Liver Dis; 2017 Nov; 37(4):314-331. PubMed ID: 29272894
[TBL] [Abstract][Full Text] [Related]
6. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
7. Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts.
Özdirik B; Schnabl B
Cell Mol Gastroenterol Hepatol; 2024; 17(3):423-438. PubMed ID: 38109970
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis.
Lapidot Y; Amir A; Ben-Simon S; Veitsman E; Cohen-Ezra O; Davidov Y; Weiss P; Bradichevski T; Segev S; Koren O; Ben-Ari Z; Safran M
Hepatol Int; 2021 Feb; 15(1):191-201. PubMed ID: 32949377
[TBL] [Abstract][Full Text] [Related]
9. Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.
Li ZJ; Gou HZ; Zhang YL; Song XJ; Zhang L
World J Gastroenterol; 2022 Nov; 28(44):6213-6229. PubMed ID: 36504550
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis.
Bajaj JS; Hays RA
Am J Gastroenterol; 2019 Jul; 114(7):1027-1029. PubMed ID: 30920413
[TBL] [Abstract][Full Text] [Related]
11. Primary sclerosing cholangitis: a clinical update.
Williamson KD; Chapman RW
Br Med Bull; 2015 Jun; 114(1):53-64. PubMed ID: 25981516
[TBL] [Abstract][Full Text] [Related]
12. Current Targets for Primary Sclerosing Cholangitis.
Pierantonelli I; Benedetti A; Marzioni M
Curr Drug Targets; 2017; 18(8):901-907. PubMed ID: 26758666
[TBL] [Abstract][Full Text] [Related]
13. Intestinal microbiota in biliary diseases.
Xia Q; Liu Q; Ma X
Curr Opin Gastroenterol; 2023 Mar; 39(2):95-102. PubMed ID: 36821457
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota in PSC : From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, January 2019.
Lemoinne S; Sabino J; Sokol H
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):123-125. PubMed ID: 31262571
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and clinical spectrum of primary sclerosing cholangitis.
Gidwaney NG; Pawa S; Das KM
World J Gastroenterol; 2017 Apr; 23(14):2459-2469. PubMed ID: 28465630
[TBL] [Abstract][Full Text] [Related]
16. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Williamson KD; Chapman RW
Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
[TBL] [Abstract][Full Text] [Related]
17. Characterization of animal models for primary sclerosing cholangitis (PSC).
Fickert P; Pollheimer MJ; Beuers U; Lackner C; Hirschfield G; Housset C; Keitel V; Schramm C; Marschall HU; Karlsen TH; Melum E; Kaser A; Eksteen B; Strazzabosco M; Manns M; Trauner M;
J Hepatol; 2014 Jun; 60(6):1290-303. PubMed ID: 24560657
[TBL] [Abstract][Full Text] [Related]
18. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.
Nakamoto N; Sasaki N; Aoki R; Miyamoto K; Suda W; Teratani T; Suzuki T; Koda Y; Chu PS; Taniki N; Yamaguchi A; Kanamori M; Kamada N; Hattori M; Ashida H; Sakamoto M; Atarashi K; Narushima S; Yoshimura A; Honda K; Sato T; Kanai T
Nat Microbiol; 2019 Mar; 4(3):492-503. PubMed ID: 30643240
[TBL] [Abstract][Full Text] [Related]
19. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy.
Bozward AG; Ronca V; Osei-Bordom D; Oo YH
Front Immunol; 2021; 12():711217. PubMed ID: 34512631
[TBL] [Abstract][Full Text] [Related]
20. The management of primary sclerosing cholangitis.
Chapman RW
Curr Gastroenterol Rep; 2003 Feb; 5(1):9-17. PubMed ID: 12530943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
